Dante Labs

What Dante Labs does

Dante Labs is a clinical-grade whole genome sequencing company founded in 2016 and headquartered in New York, with ISO 15189-, CLIA-, and CAP-accredited laboratories in Italy and the United States. The company sequences customer saliva samples at 30X coverage across all 6.4 billion base pairs of the human genome and delivers 200+ physician-ready reports — classified under ACMG guidelines — covering hereditary cancer, cardiovascular, neurological, and rare disease risk, plus pharmacogenomics. Cumulative scale is cited at over 100,000 genomes sequenced and 1.3 million reports delivered across 100+ countries. The product surface has expanded from a single DTC Whole Genome Sequencing test to include an RNA Profile transcriptomics add-on, an oncology franchise combining hereditary and somatic tumor genetics, and a Dante Omics B2B platform serving clinical institutions.

The commercial model is primarily direct-to-consumer e-commerce with one-time payments per test ($199-$999 depending on tier), augmented by annual and three-year update subscriptions and an enterprise channel through Dante Omics. Results are delivered digitally via the Genome Manager portal, which layers AI Genome Chat (plain-language NLP), automatic lifetime report updates as new variant-disease associations are validated, family profile management, and physician-ready PDF exports. The 2025 merger with Nebula Genomics, the 2021 acquisition of Cambridge Cancer Genomics, and the launch of the Dante Omics platform indicate a strategy to consolidate consumer genomics while building a clinical B2B channel. Operational signals — including a 2024 collective dismissal procedure, multi-year delivery delays, and only $150K of publicly documented external funding — indicate the company is in a turnaround posture alongside its product expansion.

Name

Dante Labs

Legal name

Dante Labs International Inc

Website

https://www.dantelabs.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Dante Labs is a clinical-grade whole genome sequencing company that sequences customer DNA at 30X coverage and delivers 200+ ACMG-classified reports across hereditary risk, rare disease, and pharmacogenomics directly to consumers in 100+ countries.

Ownership category

akta.pro rank

Product category

Clinical Genomics / Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

Keywords

• Whole genome sequencing
• Clinical genomics services
• Hereditary cancer screening
• Pharmacogenomics testing
• Rare disease diagnostics

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Whole Genome Sequencing Tests: One-time payment for genome sequencing with tiered options: Premium (core reports), All Reports Bundle (all 200+ reports + 1 year of updates), and 3 Year Updates (all reports + 3 years of updates + AI features + PRS reports). Revenue is recognized upfront upon test delivery. Additional revenue from add-ons like RNA Profile testing.
2. Subscription/Update Services: Optional subscription tiers (All Reports Bundle, 3 Year Updates) provide recurring revenue through new report delivery, proactive notifications, and automatic updates as science advances. Creates land-and-expand opportunity from initial test purchase.
3. B2B/Enterprise Genomics: Dante Genomics platform enables clinical institutions and hospitals to order and manage patient WGS testing, representing a B2B revenue stream alongside direct-to-consumer sales.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Dante Labs provides clinical-grade 30X whole genome sequencing services to consumers and clinical institutions, identifying 4.6-5 million variants per test and delivering 200+ physician-ready reports covering hereditary cancer, cardiovascular, neurological, rare diseases, and pharmacogenomics. The service is ordered via an at-home saliva collection kit with results delivered through a proprietary Genome Manager portal in 6-8 weeks.

Product overview

Dante Labs offers a modular whole genome sequencing platform anchored by its core Genome Test product with three subscription tiers (Premium, All Reports Bundle, and 3 Year Updates). The platform is accessible via the Genome Manager portal, which provides AI-powered chat functionality and automatic report updates as new variant-disease associations are discovered. Add-on modules include RNA Profile for transcriptomics analysis and a dedicated Oncology product for hereditary cancer risk and tumor genetics profiling. A B2B platform called Dante Omics serves clinical partners and healthcare institutions. The company generates over 1.3 million genomic reports delivered to customers in 100+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• Dante Omics: AI-powered B2B genomics platform launched for enterprise customers, with plans for AI features in 2025.
• Nebula Genomics
• Genome Manager

Products and services

• Genome Test (Whole Genome Sequencing) Clinical-grade 30X whole genome sequencing service that reads all 6.4 billion base pairs of DNA and identifies 4.6-5 million variants per test, delivering 200+ physician-ready clinical reports covering hereditary risk, rare diseases, pharmacogenomics, and proactive health. For consumers, clinicians, and clinical institutions.
• RNA Profile

Quantifiable outcome

• Identified pathogenic variants in periodic paralysis (1 in 100,000 prevalence) that standard panel tests had missed, enabling specialist access for two children
• +3 more outcomes

Named customers6 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Nebula GenomicscoreStrategic or Co-development PartnerDante Labs announced a merger with Nebula Genomics, another major player in the consumer and wellness genomics space. This consolidation reflects ongoing M&A activity in the genetic testing industry as companies expand their service offerings and research capabilities through strategic combinations.
• Rockefeller UniversityminorStrategic or Co-development PartnerDante Omics AI collaborated with Rockefeller University on assembling the most complete diploid reference genome for the RPE-1 cell line, contributing to precision improvements in haplotype-resolved genomics.
• Giunta LabminorStrategic or Co-development PartnerPartnered with Giunta Lab and global network of partners on reference genome assembly projects published in Nature Communications.
• Illumina, Inc.coreTechnology or IntegrationDante Labs uses Illumina sequencers (U.S.-headquartered company) for genome sequencing operations, as disclosed in Texas Genomic Act compliance documentation. Illumina equipment is specified as non-foreign-adversary compliant for Texas resident data processing.
• CLIA/CAP/ISO 15189 Accredited LaboratoriescoreTechnology or IntegrationDante maintains dual-accredited clinical laboratories (CLIA-certified, CAP-accredited, ISO 15189 accredited) in Europe and the US performing sequencing, variant classification, and clinical reporting under one accredited operation. Sample processing occurs at partner laboratory in Italy under EU jurisdiction.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Color Health: Color Health provides clinical-grade genetic testing for hereditary cancer, cardiovascular risk, and pharmacogenomics, with both DTC and B2B/employer channels. Comparable to Dante Labs on clinical-grade health testing, ACMG-aligned reporting, and a hybrid DTC-plus-enterprise go-to-market.
• Nebula Genomics: Nebula Genomics is a whole-genome sequencing DTC and B2B genomics company co-founded by George Church. It merged with Dante Labs in 2023, so it is now part of the same entity, but historically was the closest direct competitor on WGS-focused DTC testing.
• 23andMe: 23andMe is a leading direct-to-consumer genetic testing company offering ancestry, health, and trait reports. It is directly comparable to Dante Labs on the DTC WGS/genetic testing business model, though 23andMe historically used genotyping arrays rather than full WGS. Both target consumers and offer subscription tiers of health reports.
• Ancestry: Ancestry operates one of the largest consumer DNA databases, primarily focused on ancestry but expanding into health. Comparable to Dante Labs as a major DTC genetic testing brand with massive consumer reach, though it has historically used array-based genotyping rather than WGS.
• MyHeritage: MyHeritage offers DTC DNA testing for ancestry and health. It is comparable to Dante Labs on the consumer genomics DTC model and international market presence, though it is less focused on clinical-grade WGS.

Broad incumbents

• Tempus AI: Tempus AI is a large precision medicine company combining multiomics (genomics, transcriptomics, imaging) with AI for clinical and research use. Comparable to Dante Labs on the multiomics + AI + oncology positioning, but Tempus is much larger, publicly traded, and primarily B2B-focused.
• Natera: Natera is a publicly traded clinical genetic testing company specializing in reproductive health, oncology, and organ transplant monitoring. Comparable to Dante Labs on the clinical-grade genetic testing and oncology genetics axis, but operates as a much larger, broader, and primarily B2B-focused incumbent.
• Foundation Medicine: Foundation Medicine is an established oncology genomics company providing comprehensive genomic profiling of tumors to guide treatment selection. Comparable to Dante Labs on the oncology genetics and tumor profiling offering, and on physician-ready clinical reporting, though Foundation Medicine is a much larger, established enterprise incumbent.
• GeneDx: GeneDx is a clinical genomics company focused on rare disease diagnosis and pediatric genetic testing with WGS and exome offerings. Comparable to Dante Labs on clinical WGS for rare and undiagnosed disease, and on hospital/B2B channel sales to genetics teams.
• Invitae: Invitae is a large clinical genetics company offering comprehensive genetic testing across many disease areas with physician-ready reports. Comparable to Dante Labs on clinical-grade testing and ACMG-classified reports, but operates at significantly larger scale across a much broader test menu.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/dantelabs

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dante Labs